Baseline patient characteristics
| Characteristic . | Value . |
|---|---|
| Sex | |
| Men | 13 |
| Women | 1 |
| Race/ethnicity | |
| African | 3 |
| Black | 3 |
| White | 7 |
| Hispanic (Puerto Rican) | 1 |
| Median age, y (range) | 41 (28-56) |
| Median ECOG Performance Status (range) | 2 (1-3) |
| Median time since HIV diagnosis, y (range) | 6.5 (0.3-18) |
| Median time on antiretroviral therapy, y (range) | 3.5 (2 wk to 13 y) |
| HIV viral load < 50 copies/mL, no. (%) of patients | 9 (64) |
| Median CD4, cells/mL (range) | 270 (67-1319) |
| Median time since MCD diagnosis, mo (range) | 1.5 (0.5-45) |
| History of KS, no. (%) of patients | 8 (57) |
| History of KSHV-associated lymphoma, no. (%) of patients | 1 (7) |
| Prior therapies* | |
| Median no. (range) | 1 (0-7) |
| Prior therapy, no. (%) of patients | 8 (57) |
| Clinical symptoms, no. (%) of patients | |
| Fever/night sweats | 13 (93) |
| Fatigue | 13 (93) |
| Weight loss | 12 (86) |
| Respiratory symptoms | 12 (86) |
| Gastrointestinal symptoms | 11 (79) |
| Neuropathy | 5 (36) |
| Headache | 5 (36) |
| Edema | 3 (21) |
| Rash | 3 (21) |
| Myalgia | 2 (14) |
| Median biochemical parameters (range) | |
| CRP, mg/dL | 7.5 (1-35.9)† |
| Albumin, g/dL | 2.8 (1.5-3.5) |
| Sodium, mEq/L | 134 (127-142) |
| Platelets, × 103/μL | 115 (16-347) |
| Hemoglobin, g/dL | 10.1 (7.7-12.7) |
| Radiographic parameters | |
| Median spleen size, cm (range) | 18.5 (10-26.5) |
| Enlarged lymph nodes, no. of patients | 12 |
| Characteristic . | Value . |
|---|---|
| Sex | |
| Men | 13 |
| Women | 1 |
| Race/ethnicity | |
| African | 3 |
| Black | 3 |
| White | 7 |
| Hispanic (Puerto Rican) | 1 |
| Median age, y (range) | 41 (28-56) |
| Median ECOG Performance Status (range) | 2 (1-3) |
| Median time since HIV diagnosis, y (range) | 6.5 (0.3-18) |
| Median time on antiretroviral therapy, y (range) | 3.5 (2 wk to 13 y) |
| HIV viral load < 50 copies/mL, no. (%) of patients | 9 (64) |
| Median CD4, cells/mL (range) | 270 (67-1319) |
| Median time since MCD diagnosis, mo (range) | 1.5 (0.5-45) |
| History of KS, no. (%) of patients | 8 (57) |
| History of KSHV-associated lymphoma, no. (%) of patients | 1 (7) |
| Prior therapies* | |
| Median no. (range) | 1 (0-7) |
| Prior therapy, no. (%) of patients | 8 (57) |
| Clinical symptoms, no. (%) of patients | |
| Fever/night sweats | 13 (93) |
| Fatigue | 13 (93) |
| Weight loss | 12 (86) |
| Respiratory symptoms | 12 (86) |
| Gastrointestinal symptoms | 11 (79) |
| Neuropathy | 5 (36) |
| Headache | 5 (36) |
| Edema | 3 (21) |
| Rash | 3 (21) |
| Myalgia | 2 (14) |
| Median biochemical parameters (range) | |
| CRP, mg/dL | 7.5 (1-35.9)† |
| Albumin, g/dL | 2.8 (1.5-3.5) |
| Sodium, mEq/L | 134 (127-142) |
| Platelets, × 103/μL | 115 (16-347) |
| Hemoglobin, g/dL | 10.1 (7.7-12.7) |
| Radiographic parameters | |
| Median spleen size, cm (range) | 18.5 (10-26.5) |
| Enlarged lymph nodes, no. of patients | 12 |
Number of different regimens, including steroids, used to treat MCD.
CRP was assayed using Siemens Dimension Vista platform (Siemens AG); from study inception until May 2009 a standard sensitivity assay (sCRP) was used, which was subsequently replaced by a high sensitivity (hsCRP) assay. Correction of CRP for values obtained after May 2009 was performed using a formula: [sCRP = (hsCRP − 0.56)/0.93], which was validated by the National Institutes of Health Clinical Center Department of Laboratory Medicine. Normal CRP < 0.04 mg/dL.